Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn's disease: A prospective cohort study

Gastroenterology

Volumn 125, Issue 1, 2003, Pages 32-39

  Vermeire, Severine ^a   Noman, Maja ^a   Van Assche, Gert ^a   Baert, Filip ^a   Van Steen, Kristel ^b   Esters, Nele ^a   Joossens, Sofie ^a   Bossuyt, Xavier ^a   Rutgeerts, Paul ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; DOUBLE STRANDED DNA; HISTONE; INFLIXIMAB; SINGLE STRANDED DNA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTHRALGIA; ARTHRITIS; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFECT; DRUG INDUCED DISEASE; FEMALE; HUMAN; INFUSION; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROTEINURIA; RASH; SEX DIFFERENCE; SKIN MANIFESTATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0038109994     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(03)00701-7     Document Type: Article

References (30)

1. Targan SR, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman TAJ, DeWoody KL, Schaible TF, Rutgeerts P, and the Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997;337:1029-1035.
2. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJH. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117: 761-769.
3. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P, and the ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359:1541-1549.
4. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340:1398-1405.
5. Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther 1999;13(Suppl 4):16-22, discussion 38.
6. Schaible T. Long-term safety of infliximab. Can J Gastroenterol 2000;14(Suppl C):29-32.
7. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000;43:2383-2390.
8. Gordon MM, Porter DR, Capell HA. Does sulphasalazine cause drug-induced systemic lupus erythematosus? No effect evident in a prospective randomised trial of 200 rheumatoid patients treated with sulphasalazine or auranofin over five years. Ann Rheum Dis 1999;58:288-290.
9. Enzenauer RJ, West SG, Rubin RL. D-Penicillamine-induced lupus erythematosus. Arthritis Rheum 1990;33:1582-1585.
10. Chalmers A, Thompson D, Stein HE, Reid G, Patterson AC. Systemic lupus erythematosus during penicillamine therapy for rheumatoid arthritis. Ann Intern Med 1982;97:659-663.
11. Almroth G, Enestrom S, Hed J, Samuelsson I, Sjostrom P. Autoantibodies to leucocyte antigens in hydralazine-associated nephritis. J Intern Med 1992;231:37-42.
12. Merrill JT, Shen C, Gugnani M, Lahita RG, Mongey AB. High prevalence of antiphospholipid antibodies in patients taking procainamide. J Rheumatol 1997;24:1083-1088.
13. Watts RA. Musculoskeletal and systemic reactions to biological therapeutic agents. Curr Opin Rheumatol 2000;12:49-52.
14. Kalkner KM, Ronnblom L, Karlsson Parra A, Bengtsson M, Olsson Y, Oberg K. Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. Q J Med 1998;91:393-399.
15. Bell TM, Bansal AS, Shorthouse C, Sandford N, Powell EE. Low-titre autoantibodies predict autoimmune disease during interferon-alpha treatment of chronic hepatitis C. J Gastroenterol Hepatol 1999;14:419-422.
16. Ehrenstein MR, McSweeney E, Swane M, Worman CP, Goldstone AH, Isenberg DA. Appearance of anti-DNA antibodies in patients treated with interferon-alpha. Arthritis Rheum 1993;36:279-280.
17. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 2000; 95:3469-3477.
18. Farrell RJ, Shah SA, Lodhavia PJ, Alsahli M, Falchuk KR, Michetti P, Peppercorn MA. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 2000; 95:3490-3497.
19. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001;96:722-729.
20. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-1110.
21. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357: 1842-1847.
22. Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, Thriene W, Sieper J, Braun J. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000;43:1346-1352.
23. Via CS, Rus V, Shustov A, Nguyen P, Finkelman F. Administration of anti-tumor necrosis factor (TNF) monoclonal antibody (MAB) induces lupus-like auto-immunity in the parent-into-f1 (P-F1) model of acute graft versus host disease (GVHD). Arthritis Rheum 1996;39:S108.
24. Jacob CO, McDevitt HO. Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature 1988;331:356-358.
25. Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, Gordon T, Hardin JA, Kalden JR, Lahita RG, Maini RN, McDougal JS, Rothfield NF, Smeenk RJ, Takasaki Y, Wiik A, Wilson MR, Koziol JA. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 1997;40:1601-1611.
26. Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, Wolf DC, Baker JP, Hawkey C, Archambault A, Bernstein CN, Novak C, Heath PK, Targan SR for the CDP571 Crohn's Disease Study Group. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001; 120:1330-1338.
27. Bickerstaff MC, Botto M, Hutchinson WL, Herbert J, Tennent GA, Bybee A, Mitchell DA, Cook HT, Butler PJ, Walport MJ, Pepys MB. Serum amyloid P component controls chromatin degradation and prevents antinuclear auto-immunity. Nat Med 1999;5:694-697.
28. Casiano CA, Tan EM. Recent developments in the understanding of antinuclear autoantibodies. Int Arch Allergy Immunol 1996; 111:308-313.
29. Herrmann M, Zoller OM, Hagenhofer M, Voll R, Kalden JR. What triggers anti-dsDNA antibodies? Mol Biol Rep 1996;23:265-267.
30. Whitacre CC, Reingold SC, O'Looney PA, and the Task force on Gender, Multiple Sclerosis and Auto-Immunity. A gender gap in auto-immunity. Science 1999;283:1277-1278.